Inventor · disambiguated record
Tod M. Woolf
Also filed as: WOOLF TOD · WOOLF TOD M · WOOLF TOD MITCHELL
52 granted patents·28 pending applications·2,193 citations·filing 1994–2021
99Inventor score
Files withPHIO PHARM CORP15LIFE TECHNOLOGIES CORP9WOOLF TOD M8RXI PHARMACEUTICALS CORP7KHVOROVA ANASTASIA6
Top patents by PatentIndex Score
80 records- 0199US8796443B2Reduced size self-delivering RNAi compoundsKHVOROVA ANASTASIA·Filed 2009·Granted Aug 5, 2014·105 cites·19 claims
- 0298US10633654B2Modified RNAi polynucleotides and uses thereofPHIO PHARM CORP·Filed 2018·Granted Apr 28, 2020·32 cites·20 claims
- 0398US10479992B2RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionalityPHIO PHARM CORP·Filed 2017·Granted Nov 19, 2019·27 cites·20 claims
- 0498US9938530B2RNA interference in skin indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted Apr 10, 2018·25 cites·19 claims
- 0598US9303259B2RNA interference in skin indicationsRXI PHARMACEUTICALS CORP·Filed 2013·Granted Apr 5, 2016·46 cites·12 claims
- 0698US9175289B2Reduced size self-delivering RNAi compoundsRXI PHARMACEUTICALS CORP·Filed 2014·Granted Nov 3, 2015·80 cites·17 claims
- 0798US9080171B2Reduced size self-delivering RNAi compoundsKHVOROVA ANASTASIA·Filed 2011·Granted Jul 14, 2015·91 cites·15 claims
- 0898US8664189B2RNA interference in skin indicationsKHVOROVA ANASTASIA·Filed 2009·Granted Mar 4, 2014·60 cites·2 claims
- 0998US6673611B2Nucleic acid molecules with novel chemical compositions capable of modulating gene expressionSIRNA THERAPEUTICS INC·Filed 2001·Granted Jan 6, 2004·218 cites·17 claims
- 1098US5849902AThree component chimeric antisense oligonucleotidesOLIGOS ETC INC·Filed 1996·Granted Dec 15, 1998·602 cites·23 claims
- 1197US10913948B2RNA interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2018·Granted Feb 9, 2021·21 cites·7 claims
- 1297US10774330B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2015·Granted Sep 15, 2020·15 cites·19 claims
- 1397US10662430B2RNA interference in ocular indicationsPHIO PHARM CORP·Filed 2018·Granted May 26, 2020·14 cites·19 claims
- 1497US9745574B2RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionalityWOOLF TOD M·Filed 2010·Granted Aug 29, 2017·44 cites·18 claims
- 1597US9340786B2RNA interference in dermal and fibrotic indicationsKHVOROVA ANASTASIA·Filed 2011·Granted May 17, 2016·49 cites·20 claims
- 1697US5989912AThree component chimeric antisense oligonucleotidesOLIGOS ETC INC·Filed 1998·Granted Nov 23, 1999·242 cites·23 claims
- 1796US11667915B2RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionalityPHIO PHARM CORP·Filed 2019·Granted Jun 6, 2023·10 cites·20 claims
- 1896US10240149B2Reduced size self-delivering RNAi compoundsPHIO PHARM CORP·Filed 2015·Granted Mar 26, 2019·23 cites·21 claims
- 1996US10184124B2RNA interference in ocular indicationsRXI PHARMACEUTICALS CORP·Filed 2015·Granted Jan 22, 2019·23 cites·14 claims
- 2096US10041073B2Reduced size self-delivering RNAi compoundsKHVOROVA ANASTASIA·Filed 2011·Granted Aug 7, 2018·24 cites·24 claims
- 2196US9963702B2RNA interference in dermal and fibrotic indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted May 8, 2018·23 cites·20 claims
- 2296US9074211B2Inhibition of MAP4K4 through RNAIWOOLF TOD M·Filed 2009·Granted Jul 7, 2015·50 cites·11 claims
- 2395US10138485B2Neutral nanotransportersKHVOROVA ANASTASIA·Filed 2009·Granted Nov 27, 2018·22 cites·15 claims
- 2495US9095504B2RNA interference in ocular indicationsLIBERTINE LYN·Filed 2011·Granted Aug 4, 2015·50 cites·10 claims
- 2594US11118178B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2019·Granted Sep 14, 2021·8 cites·10 claims
- 2694US10876119B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2018·Granted Dec 29, 2020·7 cites·20 claims
- 2794US10815485B2RNA interference in skin indicationsPHIO PHARM CORP·Filed 2018·Granted Oct 27, 2020·8 cites·5 claims
- 2894US8815818B2Phagocytic cell delivery of RNAISAMARSKY DMITRY·Filed 2009·Granted Aug 26, 2014·60 cites·17 claims
- 2993US11584933B2RNA interference in ocular indicationsPHIO PHARM CORP·Filed 2020·Granted Feb 21, 2023·2 cites·20 claims
- 3091US9592250B2Double-stranded oligonucleotidesLIFE TECHNOLOGIES CORP·Filed 2014·Granted Mar 14, 2017·12 cites·16 claims
- 3190US11396654B2Neutral nanotransportersPHIO PHARM CORP·Filed 2018·Granted Jul 26, 2022·4 cites·19 claims
- 3290US10131904B2Modified RNAi polynucleotides and uses thereofPAVCO PAMELA A·Filed 2009·Granted Nov 20, 2018·23 cites·8 claims
- 3389US8815821B2Double-stranded oligonucleotidesWOOLF TOD·Filed 2011·Granted Aug 26, 2014·12 cites·3 claims
- 3488US9880160B2Antibody screening methodsCHEN YAN·Filed 2012·Granted Jan 30, 2018·5 cites·15 claims
- 3587US9796978B1Oligonucleotide compositions with enhanced efficiencyLIFE TECHNOLOGIES CORP·Filed 2017·Granted Oct 24, 2017·3 cites·20 claims
- 3686US11254940B2Inhibition of MAP4K4 through RNAiPHIO PHARM CORP·Filed 2015·Granted Feb 22, 2022·5 cites·9 claims
- 3785US9777275B2Oligonucleotide compositions with enhanced efficiencyLIFE TECHNOLOGIES CORP·Filed 2013·Granted Oct 3, 2017·4 cites·20 claims
- 3884USD568753SBottleIPIFINI INC·Filed 2006·Granted May 13, 2008·35 cites·1 claims
- 3980US10196640B1Oligonucleotide compositions with enhanced efficiencyLIFE TECHNOLOGIES CORP·Filed 2018·Granted Feb 5, 2019·1 cites·20 claims
- 4080US10036025B2Oligonucleotide compositions with enhanced efficiencyLIFE TECHNOLOGIES CORP·Filed 2017·Granted Jul 31, 2018·1 cites·20 claims
- 4178US10106793B2Double-stranded oligonucleotidesLIFE TECHNOLOGIES CORP·Filed 2017·Granted Oct 23, 2018·1 cites·17 claims
- 4277US2021147849A1Reduced size self-delivering rnai compoundsPHIO PHARM CORP·Filed 2020·Application pending·0 cites
- 4376US10626398B2Oligonucleotide compositions with enhanced efficiencyLIFE TECHNOLOGIES CORP·Filed 2019·Granted Apr 21, 2020·0 cites·22 claims
- 4476US8229871B2Systems and methods for computer aided inventingWOOLF TOD M·Filed 2005·Granted Jul 24, 2012·12 cites·6 claims
- 4572US5877160ACompositions and methods of treatment of androgen-associated baldness using antisense oligomersGENTA INC·Filed 1995·Granted Mar 2, 1999·45 cites·35 claims
- 4672US5693532ARespiratory syncytial virus ribozymesRIBOZYME PHARM INC·Filed 1994·Granted Dec 2, 1997·39 cites·14 claims
- 4772US2021261968A1Rna interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2021·Application pending·0 cites
- 4869US11629434B2Antibody screening methodsX BODY INC·Filed 2020·Granted Apr 18, 2023·0 cites·10 claims
- 4968US2010298408A1Oligonucleotide Compositions with Enhanced EfficiencyLIFE TECHNOLOGY CORP·Filed 2009·Application pending·0 cites
- 5067US2015099797A1Oligonucleotide compositions with enhanced efficiencyLIFE TECHNOLOGIES CORP·Filed 2014·Application pending·0 cites
Showing the top 50 of 80 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tod M. Woolf files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →